Cited 13 times in
Usefulness of intraductal RFA in patients with malignant biliary obstruction
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조재희 | - |
dc.date.accessioned | 2020-09-30T16:48:08Z | - |
dc.date.available | 2020-09-30T16:48:08Z | - |
dc.date.issued | 2020-08 | - |
dc.identifier.issn | 0025-7974 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/179626 | - |
dc.description.abstract | Background/aims: Intraductal radiofrequency ablation (ID-RFA) is a novel therapy for unresectable malignant biliary obstructions. ID-RFA for perihilar lesions is associated with a high risk of adverse events. We aimed to evaluate the feasibility and efficacy of temperature-controlled ID-RFA for perihilar malignant biliary obstruction. Methods: Sixteen patients with pathologically proven perihilar cholangiocarcinoma were prospectively enrolled to evaluate the feasibility of hilar ID-RFA. Clinical efficacy and outcomes were subsequently evaluated in a multicenter retrospective cohort. Results: Nine of the 16 patients in the prospective cohort had Bismuth type IV and 7 had type IIIA perihilar cholangiocarcinoma. The median length of stricture was 34.5 mm. The median number of ID-RFA sessions was three, and all sessions were technically and functionally successful without severe adverse events. Clinical outcomes were assessed using a multicenter hilar ID-RFA cohort of 21 patients; the median stent patency and overall survival were 90 days (range: 35-483 days) and 147 days (range: 92-487 days), respectively. An approximate 16-month patency of the bile duct was maintained in one patient who had an intraductal growth pattern. In a comparison of the self-expandable metallic stent (SEMS) and plastic stent (PS) after hilar ID-RFA, no differences in stent patency (89 vs 90.5 days, respectively; P = .912) and adverse events (20.0% vs 10%, respectively; P = .739) were observed. Conclusions: ID-RFA at 7 W for 120 seconds is safe and feasible in patients with advanced perihilar cholangiocarcinoma. After ID-RFA, SEMS and PS placement showed comparable patency and survival rates. Trial registration number: KCT0003223. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Lippincott Williams & Wilkins | - |
dc.relation.isPartOf | MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Usefulness of intraductal RFA in patients with malignant biliary obstruction | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Sung Yong Han | - |
dc.contributor.googleauthor | Dong Uk Kim | - |
dc.contributor.googleauthor | Dae Hwan Kang | - |
dc.contributor.googleauthor | Dong Hoon Baek | - |
dc.contributor.googleauthor | Tae Hoon Lee | - |
dc.contributor.googleauthor | Jae Hee Cho | - |
dc.identifier.doi | 10.1097/MD.0000000000021724 | - |
dc.contributor.localId | A03902 | - |
dc.relation.journalcode | J02214 | - |
dc.identifier.eissn | 1536-5964 | - |
dc.identifier.pmid | 32872053 | - |
dc.contributor.alternativeName | Cho, Jae Hee | - |
dc.contributor.affiliatedAuthor | 조재희 | - |
dc.citation.volume | 99 | - |
dc.citation.number | 33 | - |
dc.citation.startPage | e21724 | - |
dc.identifier.bibliographicCitation | MEDICINE, Vol.99(33) : e21724, 2020-08 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.